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Chapter
Intestinal Barrier Dysfunction, 
Bacterial Translocation and 
Inflammation: Deathly Triad in 
Sepsis
Bercis Imge Ucar and Gulberk Ucar
Abstract
Sepsis, as a complex entity, comprises multiple pathophysiological mechanisms 
which bring about high morbidity and mortality. The previous studies showed that 
the gastrointestinal tract is damaged during sepsis, and its main symptoms include 
increased permeability, bacterial translocation (BT), and malabsorption. BT is 
the invasion of indigenous intestinal bacteria via the gut mucosa to other tissues. 
It occurs in pathological conditions such as disruption of the intestine’s ecological 
balance and mucosal barrier permeability, immunosuppression, and oxidative 
stress through transcellular/paracellular pathways and initiate an excessive systemic 
inflammatory response. Thereby, recent clinical and preclinical studies focus on the 
association between sepsis and intestinal barrier dysfunction. This chapter over-
views the current knowledge about the molecular basis of BT of the intestine, its 
role in the progress of sepsis, detection of BT, and actual therapeutic approaches.
Keywords: bacterial translocation, intestinal barrier, inflammation, sepsis, multiple 
organ failure
1. Introduction
Sepsis has been announced to be a global health priority by the World Health 
Organization as in 2017, 48.9 million sepsis cases and 11 million sepsis-related deaths 
were reported worldwide [1, 2]. However, although significant progress has been made 
regarding the mechanism of sepsis, treatment modalities still have not gone beyond 
fluid resuscitation, vasopressors, antibiotics, and palliative care, after all [1, 3].
Sepsis is a perilous condition caused by the dysregulated and hyperactive host 
response to the pathogen. This response leads to an inflammation out of control and 
eventually multiple organ dysfunction syndrome (MODS), which is the primary 
cause of sepsis-related deaths. The propulsive force of the severe consequences 
of sepsis, such as MODS, is the intestines due to its potential to provoke systemic 
immune response via the injured intestinal epithelia losing its barrier function, and 
cannot prevent the pathogens and toxins to confined intraluminally and secret-
ing and releasing the pro-inflammatory cytokines into the circulation [1, 3–9]. In 
this chapter, we aimed to cover the fate of the intestinal barrier (IB) and bacterial 
translocation (BT) during sepsis along with diagnostic methods and potential 
therapeutic options for IB dysfunction in the light of this information.
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2. Structure and functions of the IB
The mammalian IB is responsible for fulfilling two primary tasks: to absorb the 
ingested nutrients and to prevent the microorganisms, toxins, allergens, as well as 
luminal pro-inflammatory factors from passing through the luminal surface of the 
intestines into the circulatory system [6, 10–13].
The gastrointestinal tract, which consists of the mouth, esophagus, stomach, 
small and large intestines, calls for a single layer epithelial lining with its partners 
in crime, such as cells of innate and adaptive immune system, forming a multifunc-
tional system to fulfill its barrier function [11].
In the name of intestinal homeostasis, “some” (capital S should be replaced with 
lowercase “s”. ome of the complex functions should be performed alongside the 
absorption of the nutrients like to prevent the trespassing of the pathogens, toxins, 
or allergens limiting the pathogenic bacterial growth to maintain the balance of 
the luminal microbiota, detoxification of the endotoxins, and immune response 
on demand as it is the largest lymphoid organ of the body by a multilayer morpho-
functional barrier [9, 14] (for a recent review, see  reference [13]).
2.1 First line of defense: commensal microbiota as the biological barrier
Human beings are in a symbiotic relationship with millions of bacteria, fungi, 
and viruses colonized in our gastrointestinal tract [12, 15, 16]. This host-commensal 
relationship, which starts at birth, even in-utero [17–19], maintains the intestinal 
homeostasis as a biological barrier and responsible for the differentiation, growth, 
and integrity of the intestinal epithelium [12, 15, 16]. Most of the species of com-
mensal bacteria are obligate anaerobes, and the rest are facultative anaerobes and 
aerobic bacteria (Table 1) [16, 20]. The majority of the anaerobic bacteria are found 
in the colon as the oxygen tension is relatively low, whereas the aerobic bacteria are 
prone to reside in the small intestines [21]. The bacterial population in the proximal 
small intestines and the colon are around 104 ml−1 and ∼107 ml−1, respectively [22].
These coexisting symbiotic bacteria demonstrate immunologic and metabolic 
functions and protect the intestines from pathogenic bacteria growth via alimen-
tary competition and colonization suppression. They help ferment and digest 
carbohydrates and synthesize vitamin B and K, along with short-chain fatty acids, 
which will then become the energy source for the intestinal epithelium. They are 
also responsible for the deconjugation of bile acids which will then reenter the 
enterohepatic circulation [12, 16].









The intestinal microbiota: Most common commensal anaerobic bacteria species in the human intestines (95% 
of them are obligate and 5% are facultative anaerobes) [16].
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The intestinal immune system is modulated via the collaboration between the 
gut microbiota with the adaptive and innate immune systems, which is carried out 
by interacting pathogen-associated molecular patterns (PAMPs) with the specific 
receptors in the intestinal immune cells [12, 16].
2.2 Second line of defense: intestinal alkaline phosphatase (IAP)
IAP, one of four of the human alkaline phosphatase family, is an intestinal 
epithelial cell-derived enzyme constantly staying active intraluminally and in the 
mucosal lining to ease the gut’s inflammatory response triggered by PAMPs. This 
way, it regulates the pH balance of the duodenal surface via bicarbonate secretion, 
helps the absorption of the long-chain fatty acids, defends the brush border mem-
brane against the members of the intestinal microbiota. IAP also dephosphorylates 
bacterial endotoxin lipopolysaccharide (LPS) and pro-inflammatory nucleotides. 
Hence, it prevents the inhibition of the commensal microorganisms, as they are 
affected by the excessive luminal ATP by removing the phosphate groups from 
adenosine di- and triphosphate. LPS, which causes a systemic immune response 
and septic shock, is located on the wall of gram-negative bacteria and shows these 
effects by binding to toll-like receptor 4 (TLR4) thanks to its Lipid A moiety. 
TLR4 is expressed both in myeloid-borne immune cells (dendritic cells (DCs), 
macrophages, and monocytes) and in non-immune cells (i.e., endothelial cells) 
[23]. When dephosphorylated Lipid A moiety binds to TLR4, LPS shifts to a TLR4 
antagonist, diminishes the pro-inflammatory cytokines, and activates nuclear 
factor-kappa-B (NF-κB), thereby minimizing the inflammatory response. It was 
previously shown that even being exposed to a lethal dose of E.coli, 80% of the 
mice survived with the help of IAP treatment. Thus, it was concluded that micro-
biota dysbiosis, intestinal inflammatory response, and transmigration of bacteria 
are inevitable in the absence of IAP [5, 14, 24, 25].
2.3 Third line of defense: the mucous layer
The first layer of the mechanical barrier is the mucosal layer which comprises 
water (95%), soluble glycoproteins (1–10%), nucleic acids, electrolytes, and 
antibodies. Mucin, a highly glycated protein, is secreted by goblet cells (specialized 
epithelial cells located in the villi), and with the help of other secreted proteins, 
they organize into a coherent mucus layer [11, 14].
Bacteria are responsible for the degradation of the mucus, and the balance 
between the secretion and the erosion of this layer determines the functionality of the 
IB. It was previously shown that this highly glycated structure of mucin feeds com-
mensal bacteria, such as Akkermansia muciniphila, which is a gram-negative bacteria 
and gets protection from the potential pathogenic growth in return [26]. A previous 
study, in which bacterial adherence was coherently found to be elevated in the intesti-
nal epithelia of the Mucin 2−/− mice leading to mucosal barrier  dysfunction [14].
The outer intestinal mucosal layer is much looser and thicker in comparison with 
the inner layer. Therefore, the inner layer restrains the transmigration of the bacteria as 
it is tightly attached to intestinal epithelia to block the direct contact between epithelial 
cells and the bacteria. Contrarily, the outer layer retains the commensal microbiota ele-
ments to eliminate the opportunistic activity of pathogenic bacteria. For that reason, 
consistent usage of pro- and prebiotic preparations is reported to boost the number of 
commensal microbiota in order to promote mucosal barrier function [14].
Besides, the anionic residues like sialic acid or sulfate groups at the N-terminal 
of the mucin glycoprotein promote convergence of the cationic immune molecules, 
which serve as a chemical defense mechanism [27].
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2.4  Fourth line of defense: physical barrier composed of the intestinal epithelial 
layer and submucosal capillary endothelial cells
The second mechanical barrier is the polarized single layer of gut epithelial cells 
(enterocytes-responsible for the absorption, goblet-specialized in mucus production, 
enteroendocrine cells-responsible for the secretion of the intestinal hormones, Paneth 
cells-responsible for expressing the microbicidal proteins and peptides among other 
properties, and microfold cells (M cells)) besides submucosal capillary endothelial cells 
[21, 28, 29], which act as a selectively permeable interface allowing the transmigration 
of the essential nutrients, water, electrolytes, and immune factors, and preventing the 
transfer of luminal pathogenic microorganisms, antigens, and toxins to the circulatory 
system [4, 12–14, 30]. This feature of selectivity is coordinated by the paracellular 
pathway regulated by desmosomes, adherens junctions, and tight junctions (TJs), 
located at the apicolateral membrane junction, lateral membrane, and basolateral 
membrane, respectively, and the transepithelial pathway, which is maintained mainly 
by the selective transporters allowing the uptake of the nutrients [13, 14, 28, 31] (for a 
recent review about mechanobiology of TJs, see reference [32]).
2.5 Fifth line of defense: antibacterial peptides
Hence their vast Golgi and endoplasmic reticulum system Paneth cells known 
for their cytoplasmic eosinophilic granules, [33], which are exclusively found in the 
crypts of the small intestine and they the secretory cells of the intestinal mucosa 
specialized in the secretion of the antimicrobial peptides, which are crucial modula-
tors of innate immunity, as well as with neuropeptides and hormones [14, 34].
α-defensin, a ubiquitous antimicrobial peptide found in the intestine, along with 
β-defensin, has bactericidal activity, particularly against both the gram-negative 
and gram-positive bacteria, and any disturbance in the existence of these peptides 
is shown to increase predisposition to inflammatory bowel disease [14, 34].
Apart from defensins, other antimicrobial proteins such as phospholipase A2 and 
lysozyme are also secreted from Paneth cells in case of an interaction with bacteria 
or bacterial antigen [34].
Besides these Paneth cell-driven antimicrobial activities, immunoglobulin A 
(IgA), which is secreted by plasma immune cells through lamina propria (tran-
scytosis) [5, 14, 35–37], also contribute to the fifth line of defense in the IB. IgA 
either binds directly to the potential pathogenic microorganism and toxins to 
counter the unwanted colonization or epithelial injury or binds and interacts with 
immune complexes within the lamina propria to clear out these complexes to soothe 
the systemic inflammatory responses [14]. It also pumps the already translocated 
bacteria and antigens in the lamina propria back into the lumen [38].
The previous experimental studies on the B cell-deficient mice (as the IgA 
secreting plasma cells are differentiated from B cells) and the polymeric immuno-
globulin receptor (pIgR) knockout mice (as the transcytosis of IgA to the intestinal 
lumen is conducted by pIgR) noted intestinal inflammation due to faded IgA-
operated adaptive immune response is seen in both mice groups [14, 39].
2.6 Sixth line of defense: immune barrier as “the largest lymphoid organ”
As the largest immunological organ [40], the gut’s innate and adaptive immune 
system is in continuous interaction with the biological barrier to prevent the 
conversion of intestinal microbiota into pathobiota. The immune barrier consists of 
different types of cells, which are members of the gut-associated lymphoid tissue 
(GALT) like intraepithelial lymphocytes (IELs), natural killer cells (NK cells), 
innate lymphoid cells (ILCs), mast cells, and M cells (Table 2) [9, 12, 41, 42]. 
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Location Structure and functions








T cells specialized in destroying the transformed, damaged, necrotic, or 
infected intestinal epithelial cells with their cytotoxic activities regulate 
the growth and proliferation of the enterocytes. They directly contact the 
antigens, microbiota, and potential pathogens, and during this interaction, 
interleukin-15 (IL-15) activates IELs and causes them to express cytokines 
like IL-2, IL-4, IL-1 and interferon-gamma (IFNγ) excessively. Although 
IELs are mostly T cells, they possess unconventional properties compared 
to other T cells due to their unique location and tasks. These functions are 
usually in favor of the intestine as they react immediately to the pathogenic 
microorganism or antigen, block the initial attempt of trespassing and 
invasion, and inhibit unnecessary inflammatory reactions against innocuous 
antigens. Nevertheless, they may mistaken self-antigens from the pathogenic 
antigens in a chaotic inflammatory milieu and trigger a pathological 
autoimmune response.
There are two types of IELs: “type a” (induced IELs) and “type b” (natural 
IELs). Type a (induced) IELs are either CD8αβ heterodimer (Major-
Histocompatibility-Complex (MHC) class I-restricted) or CD4+ (MHC class 
II-restricted) T cells, which express an αβ T cell receptor (αβTCR). They 
arise from the naive T cells and are activated postthymically (in secondary 
lymph nodes). After contact with the peripheral antigen as a tissue-resident 
memory, T cells accumulate in the gut. Type b (natural) IELs are CD8αα 
homodimer-T cells (do not express CD8β), expressing either a γδTCR or an 
αβTCR, which are thymically derived and activated by the self-antigens (they 
can be detected in-utero) and migrate to intestinal epithelium for further 
differentiation.
The adult human jejunum predominantly contains type a IELs expressing 
CD8αβ along with αβTCR, while the ileal and colonic IELs mainly express 
αβTCR without CD4 and CD8 expression. Also, IELs are recruited in the 
small intestines via interacting with E-cadherin through their hallmark 
marker CD103 (αE integrin).
M cells Peyer’s patches M cells contact the luminal antigens via their irregular short microvilli 
located on the apical surface and translocate the pathogens to the 
lymphocytes, or the antigen-presenting cells (APCs) are carried out by the 
intraepithelial pockets under the basolateral surface, which provides acquired 
immunity via interaction between the CD4+ T cells and the presented 
peptide epitopes of the pathogens.
ILCs Scattered 
both in the 
epithelium and 
the stroma
ILCs are the coordinators of mucosal immunity as they regulate other 
functions of the other cells that are part of innate and adaptive immunity, 
and they also secrete certain effector cytokines. These functions together 
serve to orchestrate the innate immune response during infection, 
tissue damage, and inflammation in order, so the gut homeostasis is 
maintained. Based on their cytokine production, they are classified into 
three groups:
Type 1 ILCs (ILC1s): NK cells. They exclusively express IFNγ and no other 
Th-17 cell-associated cytokines. NK cells are widely in contact with the 
microorganisms or the microbial components due to their location, and 
they also interact with immune cells such as DCs, T cells, macrophages, and 
fibroblasts, and epithelial cells. Intestinal NK cells recruit peripheral NK cells 
via IFNγ production.
Type 2 ILCs (ILC2s): Cells located in the lower respiratory system along with 
the gut and mesentery. They produce TH2-associated cytokines.
Type 3 ILCs (ILC3s): Cells that produce Th-17 cytokines (IL-17 and IL-22; 
cytokines associated with gut inflammation and immunity to extracellular 
bacteria). Besides, DCs, modulated by the resident commensal bacteria, 
stimulate secretion of the antibacterial peptides from induced intestinal 
epithelial cells by activating ILC3s.
Table 2. 
Intestinal immune cells: Different types of the cells of “the largest lymphoid organ” contribute to IB function 
[9, 12, 21, 41–46].
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These cells reside in the intestinal mucosal lymphoid structures of GALT, including 
the intestinal epithelium, isolated lymphoid follicles (responsible for the local IgA 
response), and mesenteric lymph nodes the lamina propria and Peyer’s patches 
(5–10% of the follicle-associated epithelial cells) [21, 43, 44, 47] (for a recent 
review, see reference [48]).
ILCs, innate lymphoid cells; ILEs, intraepithelial lymphocytes; M cells, micro-
fold cells; NK, natural killer; Th-17 cell, T helper-17 cell.
3. Mechanism of IB dysfunction in sepsis
All of the aforementioned layers of the IB are the sole protectors of the body, 
acting as a barrier between 40 trillion luminal microorganisms [49] and the body. 
Thus they carry a heavy burden in terms of maintaining intestinal homeostasis. 
Therefore, luminal content should be deliberately compartmentalized, and filtered 
selectively via preserving intestinal integrity, otherwise increased gut perme-
ability provokes the activation of mucosal immunity via promoting BT along with 
translocating endotoxins and other pro-inflammatory antigens from lumen to the 
circulation [3, 5, 9, 14]. This catastrophic cascade can be seen during any infection 
or any incident triggering local and systemic inflammatory response generat-
ing impairment of IB integrity such as sepsis, shock, trauma, abdominothoracic 
vascular surgery, transplantation, severe burn, and intestinal/mesenteric ischemia 
and reperfusion [50–52].
3.1 BT
The concept of BT was first described in 1966 [53] and further expanded in 1979 
[54] as the transportation of indigenous bacteria through the intestinal wall into the 
mesenteric lymph nodes and other sterile organs. Translocation of PAMPs, which 
are small molecular motifs (i.e., LPS, peptidoglycan, and bacterial DNA) located 
in the microorganism, are added to this definition later on [12]. The mechanism 
behind the BT are diverse.
3.1.1 Imbalance of the intestinal flora
Intestinal microbiota can be affected by diverse factors, including gastrointestinal 
secretions, antibiotics, secreted IgA (sIgA), bile salts, and peristalsis of the intes-
tines. Overgrowth of the microbiota upsets the protective features of the beneficial 
intestinal bacteria and disrupts the first line of defense of the IB resulting in BT.
3.1.2 Dysfunction of mucosal immune function
Under physiological conditions, IgA secreted by the plasma cells has a feature 
of encapsulation of bacteria to prevent their trespassing and encapsulation of 
viruses invading the cells. It also has features enhancing the effects of lysozyme and 
complements. However, pathological processes inhibit the functionality of IgA, 
including encapsulation ability, as well as their concentration via a declined number 
of plasma cells secreting the IgA. This will eventually cause BT.
3.1.3 Increased intestinal permeability
Pathological processes such as conditions causing immunocompromisation or 
immunosuppression, MODS, severe burn injury generate BT via overgrowth of 
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intestinal microbiota, immune dysfunction of the body together with the physi-
cal intestinal injury, particularly in the mucosal barrier. Oxygen depletion (caused 
by shock, mesenteric ischemia, cardiovascular surgery, transplant surgery) [50], 
acidosis, nitric oxide (NO), as exaggerated NO production by inducible NO syn-
thase (iNOS) disturbs mitochondrial functions and cellular respiration, resulting 
in decreased ATP synthesis and accelerated apoptosis which causes mucosal injury, 
inflammatory mediators (IFN-γ, IL-4, tumor necrosis factor-α (TNF-α), platelet-acti-
vating factor (PAF), reactive oxygen species (ROS)) and endotoxins (causes edema in 
the submucosa, decreases the intestinal blood flow, villi necrosis) are primary factors 
in charge of the injured intestinal mucosal barrier and increase the intestinal perme-
ability and BT consequently [38].
3.2 Who is the victim? Who is the criminal?
Sepsis is a hazardous organ dysfunction with high mortality and morbidity rate. 
The main characteristic of sepsis is “dysregulated host response to infection” [55], 
which will eventually bring about microvascular injury, problematic perfusion, 
cellular hypoxia, and finally, shock [2–5, 15].
Intestines are usually referred to as the “star of the show” during sepsis as they 
are accused of causing MODS [4, 7, 9, 12], yet sepsis (and septic shock) also disrupts 
the intestines by impairing the perfusion of the intestinal mucosa, epithelial edema, 
initiation of excessive apoptosis and necrosis of the gut epithelia [56], coagulation-
associated local dysregulation, and cause hyperpermeability, microbiota transfor-
mation into pathobiota, BT and loss of absorptive functions [3].
3.2.1 Systemic inflammatory response
As an exaggerated inflammatory response is implicated in the pathophysiology 
of sepsis, involvement of inflammatory cells along with pro-inflammatory cyto-
kines in this process is inevitable [2–5, 15, 55].
Upregulation of the adhesion molecules in the endothelial layer of the gut, 
induced by damage-associated molecular patterns (DAMPs) and PAMPs, leads to 
migration of the neutrophils, monocytes, and macrophages to the intestinal tissue. 
Pro-inflammatory cytokines released from these recruited cells initiate local and 
systemic inflammation [5, 14]. In addition, escalated activated macrophage infiltra-
tion into the artery walls inaugurates atherogenesis [14].
Besides, pattern recognition receptors (PRR) of PAMPs (including TLRs and 
NLRs) recognize the cell wall components of the bacteria via TLRs. TLR4 recog-
nizes gram-negative bacteria, whereas TLR2 recognizes gram-positive bacteria. 
At this point, LPS-induced TLR4 activates signaling pathways either by activation 
of mitogen-activated protein kinase (MAPK) and NF-κB via MyD88-dependent 
signaling pathways or the TIR-domain-containing adapter-inducing IFN-β (TRIF)-
dependent (MyD88-independent) by TLR4 endocytosis [23]. In the MyD88-
dependent pathway, nuclear translocation of NF-κB encourages the transcription of 
pro-inflammatory genes such as IL-1 α/β, IL-6, IL-18, and TNF-α, whereas, in the 
TRIF-dependent pathway, nuclear translocation of IFN regulatory factor 3 (IRF3) 
promotes IFN-inducible genes and the type I IFNs [14, 23, 57].
TLR4 cannot bind LPS per se, needs a cofactor, CD14, which hands the LPS 
to TLR4 [14], and controls the LPS-induced endocytosis of TLR4 apart from the 
signaling pathways mentioned above [23, 58].
Although these reactions initially manifest as local inflammation, the process 
ultimately transforms into a “cytokine storm” [5, 14]. On the contrary, both the 
MyD88-dependent and TRIF-dependent signaling pathways produce pro- and 
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anti-inflammatory mediators (IL-10) synchronously [23]. Thus, although it has 
been presumed that extinguishing the hyperinflammation is beneficial in septic 
patients, an overbalance of anti-inflammatory activity causes an inadequate 
response to primary infection and makes the patient prone to secondary infections 
[5, 59, 60].
Additionally, TLR4 manages intestinal cell turnover. During sepsis, elevated 
cytokine levels shift the balance between proliferation and apoptosis of the crypt 
and villus in favor of apoptosis and necrosis of the intestinal mucosa, which 
increases the intestinal permeability as a consequence of decreased villus height, 
increased release of DAMPs which feed the inflammatory process and brings about 
ulcer development along with hemorrhage and acceleration in intestinal impair-
ment [4, 5, 56]. The elevated levels of pro-inflammatory cytokines are also shown to 
reduce the thickness of the mucus layer, the adherence of the mucus layer, and the 
luminal coverage [4, 52].
Besides, several studies reported that M cells located in the villi provide  
antigens a channel to mucosal lymphoid tissue, which is a trap where they 
encounter antigen-presenting cells (APCs). APCs present them with the help 
of MHC class II to CD4+T-cells [61]. In addition to that, DCs interact with T 
cells and B cells and selectively generate pro- and anti-inflammatory immune 
responses mostly through LPS-induced TLR-associated pathways (for a recent 
review, see reference [23]).
Inflammatory host response during sepsis may alter the layers of the IB and 
cause intestinal hyperpermeability and BT, and these alterations modulate the 
changes in the expression of the proteins of the TJs such as transmembrane proteins 
(occludin, junctional adhesion molecules, claudins) and peripheral proteins like 
zonula occludens-1 (ZO-1), which is in a relationship with actin-myosin complex of 
the cytoskeleton [11]. Furthermore, TNF-α, IL-6, and IL-1β levels can be elevated 
via activation of myosin light chain kinase (MLCK), an enzyme phosphorylating 
the myosin regulatory light chain and leading to hyperpermeability and create 
a positive feedback mechanism of MLCK activation through ZO-1 and occludin 
alterations. Aggravated systemic inflammation because of the increased permeabil-
ity leads to a futile cycle [4].
3.2.2 Sepsis-induced self-digestion of the gut
Pancreatic enzymes are shown to cause multiple organ failure via autophagy 
[62]. Sepsis-induced ischemia of the gut exacerbates self-digestion and causes 
mucosal barrier damage leading to the release of DAMPs and pro-inflammatory 
cytokines from intestinal epithelial cells [5, 63].
Proteases, including pancreatic enzymes in the intestines, also activate the 
pro-metalloproteinases (MMPs) under ischemic conditions. Enzymatic activity 
of MMPs destructs intercellular junctions via proteolytic cleavage of junctional 
proteins’ ectodomain, therefore increasing the intestinal permeability. Additionally, 
MMPs can digest the endothelial basal membrane [64].
Besides, LPS can induce expression of MMP7, and Paneth cells’ degranulation, 
which promotes gut hyperpermeability, while MMP7 itself enhances local intestinal 
inflammation and intestinal damage via activation of α-defensin, subsequently 
stimulating the release of IL-6 from ileal epithelia and macrophages. Furthermore, it 
was previously confirmed that MMP7 and MMP13 are correlated with loss of intesti-
nal integrity, inflated BT, and the development of multiple organ dysfunction [5].
After all, it has been reported in several studies that the inhibition of pancreatic 
enzymes protects the sepsis-induced intestinal autophagy and improves the overall 
progress [64, 65].
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3.2.3 Intestinal circulatory problems during sepsis
25% of the total cardiac output (up to 35% during digestion) is normally 
diverted to splanchnic vasculature [5]. Intestinal hypoperfusion can be caused 
by various reasons like mesenteric ischemia, abdominothoracic vascular surgery, 
shock, severe burns, transplantation surgery, necrotizing enterocolitis, sepsis, 
and septic shock [50], because of the redistribution of blood to protect the vital 
organs [38]. Intestines are highly sensitive to hypoperfusion as the enterocytes have 
the highest turnover rate among other fixed-cell populations in the body, with a 
lifespan of 2–6 days [3, 66]. Thus, hypoperfusion causes damage to the intestinal 
mucosal barrier [5]; moreover, the inflammation as a response to hypoperfusion 
caused by the ischemia/reperfusion further injures the intestines [3], resulting in 
loss of IB integrity, BT accompanied by systemic inflammatory response via release 
of pro-inflammatory cytokines [5, 50, 67].
In addition to that, vasodilation emerges as the pro-inflammatory cytokines 
(IFN-γ, TNF-α, IL-4, platelet-activating factor) affect vascular smooth musculature 
and endothelium, as well as capillary leakage, venous stasis, and ultimately dimin-
ished cardiac output, and hypoperfusion is seen [38, 68, 69]. Furthermore, com-
pensatory mechanisms, such as the renin-angiotensin-aldosterone system, provokes 
the release of vasoconstriction and contribute to hypoperfusion. Also, regulatory 
features of the microvasculature (arterioles, venules, and capillaries) related to 
perfusion and oxygen distribution are lost due to sepsis-induced hyperinflamma-
tion and its inevitable outcome, ROS [38, 69–71].
3.2.4 Coagulopathy
Disseminated intravascular coagulation (DIC) is still an up-to-date challenge as 
of the significant lethal problems of sepsis. It is suggested that both intravascular 
and extravascular fibrin formation are seen in sepsis-associated DIC due to coagula-
tion activation combined with fibrinolysis inhibition [72].
In sepsis, activation of coagulation is driven mainly by the tissue factor (TF) 
pathway, in which TF is derived from endothelial cells, monocytes, neutrophils, and 
liver, whereas suppression of fibrinolysis is coordinated by plasminogen activator 
inhibitor-1 (PAI-1) [5]. “Activation of coagulation”: Neutrophil activation, caused 
either by direct contact with the pathogen or damaged cell- or bacteria-originated 
small molecules cause neutrophils initially to release a significant amount of TF [73, 
74]. Later on, elastase is released from the neutrophils as well. Elastase has the abil-
ity to inhibit plasminogen together with the TF pathway, which is a crucial coagula-
tion suppressor system [75, 76]. Neutrophil extracellular traps (NETs), which are 
released from neutrophils in order to trap and eliminate the microbes, also contrib-
ute to alterations in the coagulation via activation of Factor XII due to their nega-
tively charged surfaces, fibrin formation, and competitively blocking the binding 
sites of tissue plasminogen activator (tPA) for clot degradation by fibrin cleavage 
[77–80] This explains the persevere on-going of the post-sepsis micro- and macro-
thrombosis events [81]. “Inhibition of fibrinolysis”: Sepsis-associated DIC differs 
from malignancy-associated one, since it is characterized by intensive suppression 
of fibrinolysis via overproduction of PAI-1, instead of the consumption of coagula-
tion factors, od and differs from fibrinolytic phenotype DIC, as the consequential 
effects of this suppression in sepsis-associated DIC lead to tissue hypoperfusion 
resulted in organ dysfunction. Hence, the fibrin-related markers are not safe to use 
to assess the severity of sepsis as hypofibrinogenemia is uncommon [81, 82].
Besides, antibody-mediated action in the presence of pathogens can activate 
the complement system during sepsis. Coagulation system is also affected by the 
Ple se us  Adobe Acrobat Reader to re d this book chapter for free.
Just open this sam  document with Adobe Reader.
If you do not have it, you can download it here.
You can freely access the chapter at the Web Viewer here.
Securing Connectio ...Acrobat is locking documen lo ding.com
r
File cannot be found.
Infections and Sepsis Development
10
activated complement factors via generating an epithelial surface to facilitate clot 
formation. Activated C3 also activates platelets through the alternative pathway for 
stimulating aggregation, while activated C5 stimulates endothelial and inflamma-
tory cells, inducing TF expression [83, 84]. In reverse, activated coagulation system 
can also impact the complement system. TCC production via activation of C5 is 
achieved by thrombin. Additionally, plasmin can also activate C3 and C5, forby 
other proteases of the coagulation cascade activate several complement factors like 
IXa, Xa, XIa, and XIIA [85]. These factors collectively disturb intestinal micro-
circulation and intestinal physiology and recruit the immune cells throughout the 
incidence of sepsis-associated DIC [5].
4. Diagnostic techniques
It is pretty challenging to diagnose or assess the IB function directly due to the 
invasiveness of intestinal tissue sampling. However, there are some methods or 
biomarkers that indirectly assess IB function. The measurement of biomarkers in 
urine, blood, or feces generally needs simple, non-invasive test methods.
4.1 Tissue culture methods
The tissue culture methods are based on the direct detection of intestinal bacteria 
in extraintestinal tissues. The mesenteric lymph nodes (MLN), extraintestinal tis-
sues, swabs of the intestinal wall serosa or abdominal cavity, blood, and lymph are 
subjected to bacterial culture. Living bacteria are isolated, counted, and detected using 
microscopy. Direct detection has tremendous importance; however, many factors may 
interfere with the measurement [38]. For the culture of MLN, lymph nodes are sug-
gested to be excised and be homogenized in saline. The homogenate can be inoculated 
onto Columbia blood agar and cysteine lactose electrolyte deficient media.
BT can also be measured by identifying intestinal bacteria from MLN, which is 
normally sterile [86]. For the culture of MLN, a lymph node from the mesentery 
of the terminal ileum is suggested to be excised at laparotomy and be homogenized 
in saline. Then, the homogenate can be inoculated onto Columbia blood agar and 
cysteine lactose electrolyte-free media.
4.2 Use of labeled bacteria
Radioactive tracers or plasmids are used to label bacteria for their in vivo 
detection. This method can detect the bacteria which is attached to intestinal 
mucosa-associated lymphoid tissue. However, this method can be used primarily in 
scientific research labs due to its cost and technical requirements.
Fluorescence and isotopes labeling methods are recently in use. PUC19 plasmid 
was constructed in the 1980s and was used extensively in molecular cloning and 
discrimination of gene recombination [87]. In this method, the plasmid vector 
carries the ampicillin resistance gene; the plasmid contains polyclonal restriction 
endonuclease sites, which discriminates against the positive bacteria. Thus, the 
PUC19 plasmid is introduced as an ideal tracer for demonstrating BT.
4.3 PCR techniques
Intestinal BT can be demonstrated by isolating bacterial DNA in patients’ blood 
or body fluids and then amplifying and sequencing them. The PCR detection 
method is more sensitive, has a higher positive rate, and can specifically detect 
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certain bacteria when compared to blood culture methods. PCR technic is also a 
valuable tool for detecting BT in patients with undetected infectious focus. The 
disadvantage of this method is that only the presence of bacterial debris can be 
detected, the viability and quantity of the bacteria cannot be determined, and drug 
sensitivity tests cannot be performed. The quantification of total bacterial 16S 
rDNA in plasma is used to assess human and animal systemic microbial transloca-
tion in vivo and thus is a great tool to study the role of systemic microbial products 
in disease pathogenesis and mucosal barrier function. The bacterial 16S rDNA assay 
can analyze 90% of bacterial strains, including Gram-positive and Gram-negative 
bacteria. However, the use of this assay is highly challenging because of its high 
technical demands and the risk of contamination [88].
4.4 Detection of endotoxin
Lipopolysaccharide (LPS), the integral component of the outer membrane of 
all gram-negative bacteria are shown to lead to BT. Since sepsis leads to intestinal 
submucosal edema and impairs the integrity of the mucosal barrier resulting in an 
imbalance of gut microflora and increased bacterial endotoxin-induced mucosal 
injury, endotoxin detection in the blood is a good marker of BT [38, 89].
Endotoxins can be detected in biological fluids by the Limulus amoebocyte 
lysate assay. Methods using fluorescence phage recombinant technology are also 
introduced [90].
4.5 Measurement of IB function
Several methods are used for the measurement and the evaluation of intestinal 
permeability and barrier function, such as the measurements of transepithelial 
resistance and assessment of macromolecular flux across isolated segments of GI 
tissue or colonic biopsies in Ussing chambers, measurement of permeability using 
fluorescein isothiocyanate (FITC)-dextran permeability in cell lines, morphologi-
cal measurements of the TJ components, measurement of dilution potentials, and 
polyethylene glycol (PEG) profiling to assess the pore pathways [91, 92].
4.6 Intestinal permeability
Methods used to measure intestinal permeability are based on detecting the 
passage of the molecules across the intestinal epithelium. Several markers can be 
used alone or in combination to assess intestinal fluxes. Large molecules, lipophilic 
compounds, and nutrients generally prefer the transcellular route by passing 
through the intestinal epithelial cells by endocytosis, passive diffusion, or mem-
brane transporters. On the other hand, ions and small hydrophilic molecules prefer 
the paracellular transport pathway. Thus, molecular size and structure are signifi-
cant determinants of intestinal permeability [93].
Cell culture-based models using Caco-2 or HT-29 cell lines assess electrical 
resistance and intestinal flux in vivo. In contrast, differential urinary excretion tests 
with the use of chromium-labeled EDTA (51Cr-EDTA), polyethylene glycols (PEG), 
or non-metabolizable sugars such as lactulose and mannitol are frequently used to 
measure in vivo intestinal permeability [94]. Lactulose can cross the membrane via 
the paracellular pathway, while mannitol can easily cross the intestinal epithelium 
through transcellular and paracellular routes. Multi-sugar tests are offered to assess 
intestinal permeability simultaneously [28, 95]. Ovalbumin, horseradish peroxi-
dase, dextrans, and fluorescently labeled microorganisms are used to measure the 
intestinal permeability in the blood [96]. Claudin protein levels can be measured in 
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urine samples for intestinal TJ loss since claudins play a critical role in regulating the 
paracellular barrier pathway [97].
4.7 Urinary biomarkers
Markers of microbial translocation, inflammation (IL-6), and intestinal dam-
age as well as fatty acid-binding proteins (FABP) and glutathione S-transferases 
(GSTs), which can be determined using ELISA technics, are suggested as significant 
biomarkers demonstrating intestinal epithelial cell damage. Fatty acid-binding 
proteins (FABPs) are small intracellularly or membrane-localized proteins released 
in the extracellular space in their soluble extracellularly from early after a cell or 
tissue damage. There are three main types of FABP. Liver-type FABP, intestinal-type 
FABP, and ileal FABP. During intestinal cell damage, intestinal-type FABP (I-FABP) 
is released from the enterocytes in the systemic circulation and excreted through 
the kidney [98]. Therefore, it has been suggested that I-FABP is an early biomarker 
to detect impairment of IB and injury in sepsis [99–101].
GSTs are cytosolic enzymes released when the cell membrane is damaged and 
play a crucial role in the detoxification of xenobiotics. Hence, α-GSTs are intro-
duced as intestinal biomarkers [95].
4.8 Fecal biomarkers
Inflammatory molecules such as calprotectin in feces are proposed as a fecal 
biomarker reflecting the impaired IB function [102]. Calprotectin is a small protein 
in the leukocytes and is released in the lumen upon neutrophilic infiltration of the 
gut mucosa during inflammation and can be detected using ELISA technics.
5.  Therapeutic options for the improvement of the IB dysfunction in 
sepsis
Although it has been known that BT is strongly associated with the progress of 
sepsis and septic morbidity, no decisive clinical therapy is proposed for the repair 
of the impaired IB and the treatment of sepsis [14]. However, some strategies such 
as modulation of the IB, inhibiting immoderate bacterial growth, regulating the 
effects of immune mediators, endotoxins, and NO, preventing oxidative stress, and 
improving intestinal ischemia and reperfusion injury were reported the severity of 
sepsis-associated BT [38].
5.1 Selective elimination of pathogenic bacteria
Removal of pathogenic bacteria, including gram-negative bacilli and symbiotic 
anaerobic bacteria, by the treatment with non-absorbed oral antibiotics such as 
polymyxin E, polymyxin B, amphotericin B, and tobramycin were suggested to 
reduce mortality [103, 104]. Although the treatment with non-absorbable antibiot-
ics was believed to reduce the incidence of infection by pathogenic gram-negative 
bacteria and improve mortality rates, antibiotic resistance appeared as a limiting 
factor [105]. Since sepsis is an acute disease with high morbidity and mortality in 
intensive care units leads to intestinal flora disturbance, induces IB impairment, 
causes BT, systemic inflammation, and MODS; broad-spectrum antibiotics are 
frequently used in severe sepsis treatment [106]. Antibiotics are reported to affect 
the inflammatory process and ameliorate intestinal microcirculation in sepsis [107]. 
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It was recently demonstrated that broad-spectrum antibiotics prevent BT to distant 
organs such as the liver and lungs in septic rats [108]. There is, however, evidence 
that broad-spectrum antibiotics can lead to an imbalance in the intestinal micro 
ecological environment, promote BT in sepsis, and cause drug resistance and patho-
genicity, especially when MODS develops [109]. High-dose antibiotic therapy is 
also suggested to promote the translocation of native symbiotic bacteria and induce 
an inflammatory response, leading to late-onset sepsis [110]. It was concluded that 
metronidazole, an antibacterial and antiprotozoal drug used to treat giardiasis, 
anaerobic infections, and inflammatory bowel disease, reduces colonic bacterial 
counts and improves intestinal inflammation by suppressing cellular immunity 
[111]. Erythromycin was shown to increase gastric motility by affecting the motilin 
receptors in smooth muscle cells of the stomach, facilitating gastric emptying and 
decreasing the acidity and residual gastric fluid volume [112]. Treatment with 
antibiotic combinations (vancomycin, neomycin, and polymyxin b) prevented 
the translocation of intestinal bacteria to the pancreas by inhibiting the pancreatic 
NLRP3 pathway and inhibiting intestinal-pancreatic inflammatory responses [113].
5.2 Modulation of immune function and oxidative stress
During the attack of pathogenic bacteria, which destroys the IB or at decreased 
IAP conditions and increased LPS levels, the TJs are disintegrated. Macrophages are 
activated to produce pro-inflammatory cytokines, which also activate macrophages 
in circulation and cause the transportation of bacteria and LPS into the blood circula-
tion [14, 114]. As previously mentioned, both the quantity and the functions of the 
secreted IgA diminish during pathological conditions [38]. Oral sIgA supplementa-
tion was shown to increase local sIgA levels in the intestine. Epithelial growth factor is 
suggested to promote the regeneration of intestinal mucosal epithelial cells, maintain 
the normal structure of intestinal mucosa, protect the intestinal mucosal immune 
barrier, and prevent BT [115]. Studies indicated that glutamine and growth hormone 
supplementations reduce intestinal BT and regulate inflammatory pathways [38].
Exogenous IAP administration was suggested to improve the IB function, while 
oral or enteral administration of IAP ameliorated the disintegrated IB [116, 117]. It was 
recently reported that high fat, Western-type diet-induced IB dysfunction, improved 
glucose intolerance, and orally administered IAP improved severe ulcerative colitis 
patients [118]. Since it was reported that anti-TNFα antibodies and inhibition of 
myosin light chain kinase (MLCK) prevented the impaired barrier function, treatment 
with these antibodies and inhibitors was suggested to reduce the severity of inflamma-
tory bowel diseases. As IL-13 induces the disruption of barrier function by upregula-
tion of claudin-2 expression, inhibition of IL-13 or claudin-2 seems to be proper 
targets for the treatment of BT [14]. The antimicrobial peptide cathelicidin-BF (C-BF) 
inhibited small IB dysfunction in the LPS-induced septic model in rodents [119].
Curcumin reduces the LPS/IL-1β-induced impairment of TJs [120], while 
berberine decreases the effects of LPS-mediated signaling through the Wnt/beta-
catenin pathway to restore intestinal permeability in a rat model of sepsis [121]. It 
was suggested that cortisol reduces the expression of TJ proteins by alleviating the 
glucocorticoid receptor (GR) binding to the occludin and increases paracellular 
permeability and lubiprostone prevents stress-induced IB dysfunction [122]. A new 
GR agonist, 16α-hydroxytrametenolic acid (from edible mushrooms), is suggested to 
ameliorate the barrier dysfunction through PI3K/Akt/NF-κB signaling pathway [123]. 
Metformin is introduced to be beneficial for the protection of IB dysfunction by the 
inhibition of JNK activation through the AMPKα1-dependent signaling pathway [124]. 
Treatment with resveratrol increased the expression of sirtuin-1 in obese septic mice 
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and decreased the inflammatory response. Sirtuins also play a significant role during 
the late onset of septic “hypo-inflammation”; SIRT-2 inhibition in obese septic mice 
preserved a decreased microvascular inflammation and protected against thrombotic 
events [125]. Tezosentan, a non-selective ETA and ETB receptor antagonist, improved 
intestinal microcirculation in intestinal ischemia–reperfusion injury by reversing the 
BT and cellular disintegrate of the intestinal mucosa [50]. Allopurinol, vitamin C, 
coenzyme A, Quercetin, Ginkgo biloba extract, and N-acetyl cysteine are suggested 
to inhibit ROS production, protect the cell membrane, and intestinal mucosa against 
ROS-related damage [38]. Rhubarb, the edible petioles of species and hybrids (culinary 
rhubarb) of Rheum in the family Polygonaceae, was shown to reduce intestinal BT 
and intestinal mucosal permeability through ROS scavenging and protection of the 
intestinal mucosa integrity [126]. Huoxue Jiedu Ling, a mixture of wormwood, salvia 
miltiorrhiza, white-headed weng, rhubarb, and licorice, is suggested to inhibit intes-
tinal BT and reduces the oversecretion of cytokines by macrophages [127]. Shen-Fu 
Decoction (SFD), a traditional Chinese herb formulation, has been widely used to 
treat sepsis in China. A recent study showed that SFD significantly prevented intestine 
and liver damage, relieved sepsis-induced intestinal permeability and inflammation, 
ameliorated sepsis-induced impaired intestinal permeability by regulating the expres-
sion of ZO-1, Occludin, Claudin-1, and p-VASP [128].
5.3 Probiotics
The World Health Organization (WHO) describes probiotics as “live microor-
ganisms which when administered in adequate amounts confer a health benefit 
on the host” [129]. The most known microorganisms used as probiotics are 
the Lactobacillus, Bifidobacterium genera, Enterococcus, Streptococcus, and 
Escherichia, which have been suggested to benefit some gastrointestinal disorders 
by ameliorating the gut microbiota ecosystem [130]. Prebiotics are non-digestible 
food component fibers selectively inducing the growth and activity of probiotic 
bacteria, and synbiotics are described as the mixtures of probiotics and prebiotics, 
which are expected to be more beneficial in many pathological conditions. These 
microecological regulators promote the intestinal flora by inhibiting the coloniza-
tion of exogenous bacteria and excessive growth of endogenous pathogenic bacteria, 
maintaining the ecological balance in the intestine, and reducing BT [131]. In addi-
tion, it is believed that probiotics produce bacteriocins to kill pathogens, synthesize 
IgA and reduce inflammation by stimulating regulatory lymphocytes through 
interleukin (IL)-10 and transforming growth factor signaling [132]. It was reported 
that Lactobacillus rhamnosus GG pretreatment in a septic mouse model effectively 
reduced mortality, possibly by improving intestinal permeability and modulating 
microbiota dysbiosis [133]. Studies showed that supplementation of Bifidobacterium 
breve strain Yakult and Lactobacillus casei strain Shirota as probiotics and galac-
tooligosaccharides as prebiotics reduced the incidence of infectious complications 
such as enteritis, pneumonia, and bacteremia in patients with severe SIRS compared 
to those who did not receive synbiotics [134]. Synbiotics are a potential treatment 
option for sepsis patients since the complications of enteritis, and ventilation-asso-
ciated pneumonia was significantly decreased in the patients treated with synbiotics 
[135]. However, the application of probiotics on sepsis has been limited due to the 
theoretical risk of aggravating bacteremia in patients with critical illnesses [136].
5.4 Fecal microbiota transplantation
Clinical studies showed that sepsis is influenced by gut microbiota disruption 
[137]. Fecal microbiota transplantation (FMT) is the administration of fecal material 
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from a healthy donor into a patient’s intestinal tract with an altered gut microbiota to 
restore its functions. Randomized controlled trials showed that FMT is successfully 
applied in treating recurrent C. difficile infections. In addition, it helped restore bac-
terial communities in cecal crypts crucial in protecting intestinal stem cells, preserv-
ing immunological pathways by enhancing the expression of toll-like receptors and 
introduce the short-chain fatty acids, bile acids, eukaryotic, and prokaryotic viruses 
to the intestinal ecosystem [138, 139]. It has been postulated that if the symbiosis 
between the commensal bacteria and the human host becomes imbalanced, the 
innate and adaptive immune systems are disturbed [140]. Protective anaerobes are 
lost in fecal specimens with severe sepsis, indicating that pathobiota may dysregulate 
the immune system during sepsis [137]. Thus, FMT provides the restoration of 
intensive care unit-associated dysbiosis and intestinal decolonization of multidrug-
resistant (MDR) organisms.
Furthermore, the introduction of symbiotic bacteria may decrease the antibiotic 
resistance genes present in the microbiome [139]. Treatment with FMT provides a 
complete reversal of dysbiosis, decreases the levels of inflammatory mediators, and 
normalizes T helper-(Th-)1/Th2 and Th1/Th17 ratios. However, since MDR is a 
leading cause of sepsis complications in intensive care unit patients, FMT has been 
evaluated in different case series. Results cannot be easily analyzed because of the 
high risk of bias in smaller studies, results of different studies cannot be conclusive 
because of different patient populations (with the most common organisms are 
carbapenem-resistant Enterobacteriaceae, vancomycin-resistant Enterococci, and 
extended-spectrum β-lactamase-producing bacteria, and Pseudomonas, methicil-
lin-resistant S. aureus, and Acinetobacter [141].
6. Conclusion
Sepsis is a severe life-threatening organ dysfunction resulting from a systemic 
inflammatory response to infection. BT occurs more frequently in patients with 
intestinal obstruction, endogenous infections, endotoxemia, and impaired immune 
system, which is the cause of subsequent sepsis and ultimately leads to multiple 
organ dysfunction. The present chapter focused on sepsis-induced dysfunction 
of the IB leading to BT and multiple organ dysfunction. In addition, the underly-
ing molecular mechanisms of BT in sepsis, diagnosis, and assessment of BT and 
therapeutic approaches were also discussed. Elucidating the factors affecting BT 
may lead to implementing interventions that contribute to improved patient out-
comes. Unfortunately, there are no proven beneficial therapeutic options to prevent 
sepsis-induced BT yet; however, attempts at selective gut decontamination, the use 
of pre-or probiotics, new regimes for antibiotic prophylaxis, and fecal microbiota 
transplantation, to patient care will provide significant improvement for the treat-
ment of sepsis.
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